Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
2026-03-13 09:29:43 ET
On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) , an estimated $6.54 million trade based on quarterly average pricing.
According to its SEC filing dated February 17, 2026, Sphera Funds Management Ltd. bought 374,847 additional shares of Syndax Pharmaceuticals, bringing its total to 762,563 shares. The estimated value of the shares acquired in the fourth quarter was $6.54 million, based on the period’s average closing price. The quarter-end value of the position increased by $10.06 million, a figure that includes both new purchases and changes in the stock price.
Syndax Pharmaceuticals, Inc. is a biotechnology company specializing in the development of therapies for cancer. The company's strategy centers on the commercialization of drugs, advancing its lead candidates through clinical trials, and forming strategic collaborations to accelerate commercialization.
NASDAQ: SNDX
SNDX Trading
-3.25% G/L:
$23.38 Last:
835,922 Volume:
$24.24 Open:
